Adaptive Approaches in Clinical Drug Development
暂无分享,去创建一个
Amarnath Sharma | Michael Krams | Vlad Dragalin | Daniel D. Burns | Parvin Fardipour | S. Krishna Padmanabhan | Inna Perevozskaya | Gary Littman | Robert Maguire
[1] Jeff Maca,et al. Adaptive Seamless Phase II/III Designs—Background, Operational Aspects, and Examples , 2006 .
[2] Paul Gallo,et al. Sample Size Reestimation: A Review and Recommendations , 2006 .
[3] M. Krams,et al. Adaptive Designs in Clinical Drug Development—An Executive Summary of the PhRMA Working Group , 2006, Journal of biopharmaceutical statistics.
[4] B. Turnbull,et al. Group Sequential Methods with Applications to Clinical Trials , 1999 .
[5] D. V. Lindley,et al. Prospects for the Future The Next 50 Years , 1984 .
[6] L B Sheiner,et al. Learning versus confirming in clinical drug development , 1997, Clinical pharmacology and therapeutics.
[7] M. Krams,et al. Innovative Approaches for Designing and Analyzing Adaptive Dose-Ranging Trials , 2007, Journal of biopharmaceutical statistics.
[8] J O'Quigley,et al. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.
[9] Donald A. Berry,et al. Good Practices for Adaptive Clinical Trials in Pharmaceutical Product Development , 2009 .
[10] Michael Krams,et al. Implementing Adaptive Designs: Logistical and Operational Considerations , 2006 .
[11] L. Haines,et al. Bayesian Optimal Designs for Phase I Clinical Trials , 2003, Biometrics.
[12] V. Fedorov,et al. Adaptive designs for dose-finding based on efficacy–toxicity response , 2006 .
[13] Vladimir Dragalin,et al. Adaptive Designs: Terminology and Classification , 2006 .
[14] Paul Gallo,et al. Adaptive Dose-Response Studies , 2006 .
[15] Andrew P Grieve,et al. ASTIN: a Bayesian adaptive dose–response trial in acute stroke , 2005, Clinical trials.